Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Biogen Inc (NASDAQ:BIIB)

276.57
Delayed Data
As of 4:14pm ET
 -3.41 / -1.22%
Today’s Change
205.42
Today|||52-Week Range
307.33
+5.88%
Year-to-Date
The 4 Principles That Drive PRIMECAP
3:59pm / GuruFocus News - Paid Partner Content
Nasdaq Tops 6,000 in Busy Day of Milestones for Wall Street
Apr 25 / TheStreet.com - Paid Partner Content
Stock Market News for April 26, 2017
Apr 26 / Zacks.com - Paid Partner Content
First Quadrant L P Buys Williams, LyondellBasell Industries NV, Zoetis, Sells Verizon...
Apr 25 / GuruFocus News - Paid Partner Content
Pharma Stocks Q1 Earnings Roster for Apr 27: CELG, ABBV, BMY
Apr 26 / Zacks.com - Paid Partner Content
Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down
Apr 25 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: Biogen Gains on Strong Q1, NASH Data on Gilead Drug
Apr 26 / Zacks.com - Paid Partner Content
Stocks Hold at Highs as Dow, S&P 500 Enjoy Best Two-Day Stretch of 2017
Apr 25 / TheStreet.com - Paid Partner Content
High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and D...
Apr 26 / TheStreet.com - Paid Partner Content
Biogen (BIIB) Q1 Earnings & Sales Top, Spinraza Sales Strong
Apr 25 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close279.98
Today’s open279.57
Day’s range275.60 - 281.22
Volume2,268,324
Average volume (3 months)1,649,010
Market cap$59.4B
Dividend yield--
Data as of 4:14pm ET, 04/27/2017

Growth & Valuation

Earnings growth (last year)+10.32%
Earnings growth (this year)+1.85%
Earnings growth (next 5 years)+5.90%
Revenue growth (last year)+9.37%
P/E ratio16.3
Price/Sales6.09
Price/Book4.98

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences+0.36+0.53%
ILMNIllumina Inc-0.84-0.46%
BIVVBioverativ Inc+0.15+0.26%
NBIXNeurocrine Bioscienc...+0.31+0.58%
Data as of 4:14pm ET, 04/27/2017

Financials

Next reporting dateJuly 27, 2017
EPS forecast (this quarter)$5.21
Annual revenue (last year)$10.2B
Annual profit (last year)$3.7B
Net profit margin36.32%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
Michel Vounatsos
Chief Financial Officer &
Executive Vice President
Paul J. Clancy
Corporate headquarters
Cambridge, Massachusetts

Forecasts